Aspirin and clopidogrel resistance in drug eluting stent era

Jang Young Kim, Junghan Yoon

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Platelets play a central role in the pathogenesis of atherothrombosis. Dual antiplatelet therapy with clopidogrel plus aspirin has been shown to reduce ischemic events in patients undergoing percutaneous coronary intervention (PCI) and stenting. Although dual antiplatelet therapy reduces the risk of cardiovascular episodes after PCIs, a substantial number of incidents continue to occur. Many cardiologists have focused their attention to the relationships between the interindividual variability of platelet inhibition after aspirin or clopidogrel administration and major cardiac adverse events such as stent thrombosis. Recent evidence has suggested that "aspirin or clopidogrel resistance" is associated with poor health outcomes (recurrent atherothrombotic events and stent thrombosis) after drug eluting stent (DES) implantation. However, the current clinical guidelines do not support routine screenings for antiplatelet resistance because standardized objective screening has not yet been established. Thus, this review describes the antiplatelet therapy used in PCI and it outlines the mechanism, laboratory tests, clinical impact and treatment options for aspirin and clopidogrel resistance in the DES era.

Original languageEnglish
Pages (from-to)135-147
Number of pages13
JournalKorean Circulation Journal
Issue number4
Publication statusPublished - 2007 Apr

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Aspirin and clopidogrel resistance in drug eluting stent era'. Together they form a unique fingerprint.

Cite this